3.2. Analysis.
Comparison 3 ICS versus placebo, parallel‐group studies, 2 months or less (all doses), Outcome 2 Change in FVC compared to baseline (% increase).
Comparison 3 ICS versus placebo, parallel‐group studies, 2 months or less (all doses), Outcome 2 Change in FVC compared to baseline (% increase).